Machine Learning Reveals Protein Signatures in CSF and Plasma Fluids of Clinical Value for ALS

被引:29
作者
Bereman, Michael S. [1 ,2 ,3 ]
Beri, Joshua [2 ]
Enders, Jeffrey R. [3 ]
Nash, Tara [3 ]
机构
[1] North Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA
[2] North Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA
[3] North Carolina State Univ, Ctr Human Hlth & Environm, Raleigh, NC 27695 USA
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
关键词
AMYOTROPHIC-LATERAL-SCLEROSIS; CEREBROSPINAL-FLUID; BIOMARKER DISCOVERY; ALZHEIMERS-DISEASE; RETINOIC ACID; COMPLEMENT; SERUM; OVEREXPRESSION; IDENTIFICATION; ASTROCYTES;
D O I
10.1038/s41598-018-34642-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We use shotgun proteomics to identify biomarkers of diagnostic and prognostic value in individuals diagnosed with amyotrophic lateral sclerosis. Matched cerebrospinal and plasma fluids were subjected to abundant protein depletion and analyzed by nano-flow liquid chromatography high resolution tandem mass spectrometry. Label free quantitation was used to identify differential proteins between individuals with ALS (n = 33) and healthy controls (n = 30) in both fluids. In CSF, 118 (p-value < 0.05) and 27 proteins (q-value < 0.05) were identified as significantly altered between ALS and controls. In plasma, 20 (p-value < 0.05) and 0 (q-value < 0.05) proteins were identified as significantly altered between ALS and controls. Proteins involved in complement activation, acute phase response and retinoid signaling pathways were significantly enriched in the CSF from ALS patients. Subsequently various machine learning methods were evaluated for disease classification using a repeated Monte Carlo cross-validation approach. A linear discriminant analysis model achieved a median area under the receiver operating characteristic curve of 0.94 with an interquartile range of 0.88-1.0. Three proteins composed a prognostic model (p = 5e-4) that explained 49% of the variation in the ALS-FRS scores. Finally we investigated the specificity of two promising proteins from our discovery data set, chitinase-3 like 1 protein and alpha-1-antichymotrypsin, using targeted proteomics in a separate set of CSF samples derived from individuals diagnosed with ALS (n = 11) and other neurological diseases (n = 15). These results demonstrate the potential of a panel of targeted proteins for objective measurements of clinical value in ALS.
引用
收藏
页数:14
相关论文
共 75 条
[1]   The human plasma proteome - History, character, and diagnostic prospects [J].
Anderson, NL ;
Anderson, NG .
MOLECULAR & CELLULAR PROTEOMICS, 2002, 1 (11) :845-867
[2]  
ANNUNZIATA P, 1985, ACTA NEUROL SCAND, V72, P61
[3]  
Anoop A, 2010, Int J Alzheimers Dis, V2010, DOI 10.4061/2010/606802
[4]   SERUM AND CSF IMMUNOLOGICAL FINDINGS IN ALS [J].
APOSTOLSKI, S ;
NIKOLIC, J ;
BUGARSKIPROKOPLJEVIC, C ;
MILETIC, V ;
PAVLOVIC, S ;
FILIPOVIC, S .
ACTA NEUROLOGICA SCANDINAVICA, 1991, 83 (02) :96-98
[5]   An Automated Pipeline to Monitor System Performance in Liquid Chromatography-Tandem Mass Spectrometry Proteomic Experiments [J].
Bereman, Michael S. ;
Beri, Joshua ;
Sharma, Vagisha ;
Nathe, Cory ;
Eckels, Josh ;
MacLean, Brendan ;
MacCoss, Michael J. .
JOURNAL OF PROTEOME RESEARCH, 2016, 15 (12) :4763-4769
[6]   Implementation of Statistical Process Control for Proteomic Experiments Via LC MS/MS [J].
Bereman, Michael S. ;
Johnson, Richard ;
Bollinger, James ;
Boss, Yuval ;
Shulman, Nick ;
MacLean, Brendan ;
Hoofnagle, Andrew N. ;
MacCoss, Michael J. .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2014, 25 (04) :581-587
[7]   The development of selected reaction monitoring methods for targeted proteomics via empirical refinement [J].
Bereman, Michael S. ;
MacLean, Brendan ;
Tomazela, Daniela M. ;
Liebler, Daniel C. ;
MacCoss, Michael J. .
PROTEOMICS, 2012, 12 (08) :1134-1141
[8]   High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia [J].
Bergmann, OJ ;
Johansen, JS ;
Klausen, TW ;
Mylin, AK ;
Kristensen, JS ;
Kjeldsen, E ;
Johnsen, HE .
CLINICAL CANCER RESEARCH, 2005, 11 (24) :8644-8652
[9]   APPLYING PROTEOMICS TO THE DIAGNOSIS AND TREATMENT OF ALS AND RELATED DISEASES [J].
Bowser, Robert ;
Lacomis, David .
MUSCLE & NERVE, 2009, 40 (05) :753-762
[10]   Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS) [J].
Brettschneider, Johannes ;
Lehmensiek, Vera ;
Mogel, Helga ;
Pfeifle, Martin ;
Dorst, Johannes ;
Hendrich, Corinna ;
Ludolph, Albert C. ;
Tumani, Hayrettin .
NEUROSCIENCE LETTERS, 2010, 468 (01) :23-27